10)Horwitz S, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. The gene discussed is TNFRSF8; the disease is peripheral T-cell lymphoma, not otherwise specified.